Table 2: Meta-analysis statistical summary on relationship of dietary omega 3 and omega 6 compound with prostate cancer risk.

Dietary compound intakeNumber of studies (population size)Total prostate cancer incidenceSensitivity analysis

Total omega 32 studies (93,047)RR: 0.973; 95% CI: 0.888, 1.065; ; %
ALA5 studies (228,668)RR: 0.956; 95% CI: 0.855, 1.070; ; %
ALA (adjusted)4 studies (177,133)RR: 0.915; 95% CI: 0.849, 0.985; ; %
EPA4 studies (196,192)RR: 0.996; 95% CI: 0.921, 1.076; ; %
EPA (adjusted)3 studies (151,326)RR: 1.049; 95% CI: 0.955, 1.152; ; %
DHA4 studies (196,192)RR: 0.990; 95% CI: 0.918, 1.068; ; %
DHA (adjusted)3 studies (196,192) RR: 1.032; 95% CI: 0.944, 1.128; ; %
Long-chain 3 studies (75,597)RR: 1.058; 95% CI: 0.876, 1.280; ; %
Long-chain (adjusted)2 studies (30,731)RR: 1.135; 95% CI: 1.008, 1.278; ; %
Long-chain + (DHA + EPA)4 studies (82,483)RR: 1.034; 95% CI: 0.973, 1.096; ; %
Total omega 63 studies (111,361)RR: 1.038; 95% CI: 0.951, 1.133; ; %
Linoleic acid4 studies (115,711)RR: 0.972; 95% CI: 0.859, 1.101; ; %
Arachidonic acid3 studies (113,709)RR: 1.093; 95% CI: 0.973, 1.226; ; %